Journal of Traditional Medical Complementary Therapies

.: REVIEW
Connection of Ganoderma Lucidum with Health
Ganoderma Lucidum'un Sağlık ile İlişkisi
F. Hümeyra ZENGİNa, Nevin ŞANLIERb
aAnkara Training and Research Hospital, Clinic of Nutrition and Diet, Ankara, TURKEY
bAnkara Medipol University Faculty of Health Sciences, Department of Nutrition and Dietetics, Ankara, TURKEY
J Tradit Complem Med. 2020;3(1):84-98
doi: 10.5336/jtracom.2019-71988
Article Language: EN
Full Text
ABSTRACT
 Ganoderma lucidum (G. lucidum) has been called the 'mushroom of immortality' for 2.000 years. The mushroom is composed of bioactive components, such as various proteins, sterols, lectins, and fatty acids, including polysaccharides and triterpenoids. The bioactive components of G. lucidum, as a medical mushroom, has been widely used to improve public health and to treat diseases in many populations for a long time. Clinical and pharmacological studies showed that G. lucidum is composed of hundreds of bioactive components with immunomodulatory, antioxidant, antiaging, antiviral, antitumor, antiobesity, and protective effects on the liver and neurons and against human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS) through different parts of the mushroom, such as the fruit, mycelium, and spores. In addition, the components of G. lucidum are one of the important prebiotics used to strengthen the bacterial flora. The prebiotic property of G. lucidum is thought to be due to the presence of various polysaccharides. It does not show any negative or toxic effect while exhibiting its potential health effects and its cost is lower than drugs. It prevents the formation and progression of various diseases. Further study will benefit the determination of the efficacy of G. lucidum, the elucidation of other possible biological activities, the development of recommendations, and the provision of evidence in relation to other diseases. In this study; bioactive components and health effects of G. Lucidum were reviewed through selected web sites including MEDLINE, Embase, Cochrane Central, www.ClinicalTrials.gov, PubMed, Science Direct, Google Scholar.

Keywords: Ganoderma lucidum; antioxidants; immunomodulation; anti-obesity agents; toxicity
ÖZET
 Ganoderma lucidum (G. lucidum), 2000 yıldır 'ölümsüzlük mantarı' olarak adlandırılmaktadır. Bu mantar; polisakkaritler ve triterpenoitler dahil olmak üzere çeşitli proteinler, steroller, lektinler ve yağ asitleri gibi biyoaktif bileşenlerden oluşmaktadır. Tıbbi bir mantar olarak G. lucidum'un biyoaktif bileşenleri, halk sağlığını geliştirmek ve birçok popülasyondaki hastalıkları tedavi etmek için yaygın olarak birçok ülkede kullanılmaktadır. İnsan sağlığını koruması ve birçok hastalığın tedavisinde kullanılması nedeniyle G. lucidum'un toz formu, çayları, kahvesi, diyet suplemanı gibi sayısız çeşidi piyasaya sürülmüştür. Klinik ve farmakolojik çalışmalar G. lucidum'un meyve, miselyum ve sporlar gibi farklı kısımlarından elde edilen biyoaktif bileşenlerinin güçlü anti-kanser aktivitesinin olduğunu, tümör oluşmadan önce kanser hücrelerini arayabilen ve yok edebilen bağışıklık sistemini geliştirdiği, immünomodülatör, antioksidant, antiaging, antiviral, antidiyabetik, antiobezite, nöronlar, karaciğer ve İnsan İmmün Yetmezlik Virüsü (HIV)/Kazanılmış Bağışıklık Yetersizliği Sendromu (AIDS)'e karşı koruyucu etkisinin olduğu bildirilmektedir. Ayrıca, G. lucidum'un bileşenleri, bakteri florasını güçlendirmek için kullanılan önemli prebiyotiklerden biridir. G. lucidum'un prebiyotik özelliğinin, çeşitli polisakaritlerin varlığından kaynaklandığı düşünülmektedir. Olası sağlık etkilerini gösterirken herhangi bir olumsuz ve toksik etki göstermemekte ve maliyeti açısından da ilaçlardan daha avantajlı olmaktadır. İleriki çalışmalar, G. lucidum'un etkinliğinin, diğer olası biyolojik aktivitelerin aydınlatılmasının, önerilerin geliştirilmesinin ve diğer hastalıklarla ilgili kanıtların sağlanmasının belirlenmesinde faydalı olacaktır. Bu derlemede; G. lucidum'un biyoaktif bileşenleri ve sağlık etkileri MEDLINE, Embase, Cochrane Central, www.Clinical Trials.gov, PubMed, Science Direct, Google Scholar gibi seçilmiş web siteleri aracılığıyla irdelenmiştir.

Anahtar Kelimeler: Ganoderma lucidum; antioksidanlar; immünmodülasyon; antiobezite ajanları; zehirlilik
REFERENCES:
  1. Wang XC, Xi RJ, Li Y, Wang DM, Yao YJ. The species identity of the widely cultivated Ganoderma, 'G. lucidum' (Ling-zhi), in China. PLoS One. 2012;7(7):e40857. [Crossref]  [PubMed]  [PMC] 
  2. Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. Ganoderma lucidum (Lingzhi or Reishi): a medicinal mushroom. In: Benzie IFF, Wachtel-Galor S, eds. Herbal Medicine: Biomolecular and Clinical Aspects. Chapter 9. 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis; 2011.
  3. Leskosek-Cukalovic I, Despotovic S, Lakic N, Niksic M, Nedovic V, Tesevic V. Ganoderma lucidum-medical mushroom as a raw material for beer with enhanced functional properties. Food Research International. 2010;43(9):2262-9. [Crossref] 
  4. Nahata A. Ganoderma lucidum: a potent medicinal mushroom with numerous health benefits. Pharmaceut Anal Acta. 2013;4(10):e159.
  5. Chen C, Li P, Li Y, Yao G, Xu JH. Antitumor effects and mechanisms of ganoderma extracts and spores oil. Oncol Lett. 2016;12(5):3571-8. [Crossref]  [PubMed]  [PMC] 
  6. Rathee S, Rathee D, Rathee D, Kumar V, Rathee P. Mushrooms as therapeutic agents. Revista Brasileira de Farmacognosia. 2012;22(2):459-74. [Crossref] 
  7. Choi S, Nguyen VT, Tae N, Lee S, Ryoo S, Min BS, et al. Anti-inflammatory and heme oxygenase-1 inducing activities of lanostane triterpenes isolated from mushroom Ganoderma lucidum in RAW264.7 cells. Toxicol Appl Pharmacol. 2014;280(3):434-42. [Crossref]  [PubMed] 
  8. Ulziijargal E, Mau J. Nutrient compositions of culinary-medicinal mushroom fruiting bodies and mycelia. Int J Med Mushrooms. 2011;13(4):343-9. [Crossref]  [PubMed] 
  9. Ferreira IC, Heleno SA, Reis FS, Stojkovic D, Queiroz MJ, Vazconcelos MH, et al. Chemical features of Ganoderma polysaccharides with antioxidant, antitumor and antimicrobial activities. Phytochemistry. 2015;114:38-55. [Crossref]  [PubMed] 
  10. Bishop KS, Kao CH, Xu Y, Glucina MP, Paterson RR, Ferguson LR. From 2000 years of Ganoderma lucidum to recent developments in nutraceuticals. Phytochemistry. 2015;114:56-65. [Crossref]  [PubMed] 
  11. Gao Y, Tang W, Gao H, Chan E, Lan J, Zhou S. Ganoderma lucidum polysaccharide fractions accelerate healing of acetic acid-induced ulcers in rats. J Med Food. 2004;7(4):417-21. [Crossref]  [PubMed] 
  12. Rasjidi I, Susanto C. Ganoderma lucidum polysaccharide peptide (GLPP) for the cancer treatment. Indones J Clin Pharm. 2015;4(2):120-8. [Crossref] 
  13. Kan Y, Chen T, Wu Y, Wu J, Wu J. Antioxidant activity of polysaccharide extracted from Ganoderma lucidum using response surface methodology. Int J Biol Macromol. 2015;72:151-7. [Crossref]  [PubMed] 
  14. Xiao C, Wu Q, Zhang J, Xie Y, Cai W, Tan J. Antidiabetic activity of Ganoderma lucidum polysaccharides F31 downregulated hepatic glucose regulatory enzymes in diabetic mice. J Ethnopharmacol. 2017;196:47-57. [Crossref]  [PubMed] 
  15. Cheng S, Sliva D. Ganoderma lucidum for cancer treatment: we are close but still not there. Integr Cancer Ther. 2015;14(3):249-57. [Crossref]  [PubMed] 
  16. Chen S, Li X, Yong T, Wang Z, Su J, Jiao C, et al. Cytotoxic lanostane-type triterpenoids from the fruiting bodies of Ganoderma lucidum and their structure-activity relationships. Oncotarget. 2017;8(6):10071-84. [Crossref] 
  17. Girjal VU, Neelagund S, Krishnappa M. Antioxidant properties of the peptides isolated from Ganoderma lucidum fruiting bodies. Int J Pept Res Ther. 2012;18:319-25. [Crossref] 
  18. Cör D, Knez Ž, Knez Hrnčič M. Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of ganoderma lucidum terpenoids and polysaccharides: a review. Molecules. 2018;23(3):649. [Crossref]  [PubMed]  [PMC] 
  19. Bao DP, Bai R, Gao YN, Wu YY, Wang Y. Computational Insights into the molecular mechanism of the high ımmunomodulatory activity of LZ-8 protein ısolated from the lingzhi or reishi medicinal mushroom ganoderma lucidum (Agaricomycetes). Int J Med Mushrooms. 2018;20(6):537-48. [Crossref]  [PubMed] 
  20. Popović V, Źivković J, Davidović S, Stevanović M, Stojković D. Mycotherapy of cancer: an update on cytotoxic and antitumor activities of mushrooms, bioactive principles and molecular mechanisms of their action. Curr Top Med Chem. 2013;13(21):2791-806. [Crossref]  [PubMed] 
  21. Kumakura K, Hori C, Matsuoka H, Igarashi K, Samejima M. Protein components of water extracts from fruiting bodies of the Reishi mushroom Ganoderma lucidum contribute to the production of functional molecules. J Sci Food Agric. 2018;99(2):529-35. [Crossref]  [PubMed] 
  22. Lv GP, Zhao J, Duan JA, Tang YP, Li SP. Comparison of sterols and fatty acids in two species of Ganoderma. Chem Cent J. 2012;6(1):10. [Crossref]  [PubMed]  [PMC] 
  23. Gurovic MSV, Viceconte FR, Pereyra MT, Bidegain MA, Cubitto MA. DNA damaging potential of Ganoderma lucidum extracts. J Ethnopharmacol. 2018;10(217):83-8. [Crossref]  [PubMed] 
  24. Gao P, Hirano T, Chen Z, Yasuhara T, Nakata Y, Sugimoto A. Isolation and identification of C-19 fatty acids with anti-tumor activity from the spores of Ganoderma lucidum (reishi mushroom). Fitoterapia. 2012;83(3):490-9. [Crossref]  [PubMed] 
  25. Hou CT, Lin JT, Dulay RMR, Ray K. Identification of molecular species of acylglycerols of Philippine wild edible mushroom, Ganoderma lucidum. Biocatalysis and Agricultural Biotechnology. 2017;9:19-27. [Crossref] 
  26. Chen S, Yong T, Zhang Y, Su J, Jiao C, Xie Y. Anti-tumor and anti-angiogenic Ergosterols from Ganoderma lucidum. Front Chem. 2017;5:85. [Crossref]  [PubMed]  [PMC] 
  27. Zhang CR, Yang SP, Yue JM. Sterols and triterpenoids from the spores of Ganoderma lucidum. Nat Prod Res. 2008;22(13):1137-42. [Crossref]  [PubMed] 
  28. Ge FH, Duan MH, Li J, Shi QL. Ganoderin A, a novel 9,11-secosterol from Ganoderma lucidum spores oil. J Asian Nat Prod Res. 2017;19(12):1252-7. [Crossref]  [PubMed] 
  29. Zhao ZZ, Chen HP, Feng T, Li ZH, Dong ZJ, Liu JK. Lucidimine A-D, four new alkaloids from the fruiting bodies of Ganoderma lucidum. J Asian Nat Prod Res. 2015;17(12):1160-5. [Crossref]  [PubMed] 
  30. Chen Y, Lan P. Total syntheses and biological evaluation of the ganoderma lucidum alkaloids lucidimines B and C. ACS Omega. 2018;3(3):3471-81. [Crossref]  [PubMed]  [PMC] 
  31. Bach EE, Bach Hi EM, Martins AMC, Nascimento PAM, Yamashita Wadt NSY. Hypoglicemic and hypolipedimic effects of ganoderma lucidum in streptozotocin-ınduced diabetic rats. Medicines. 2018;5:78. [Crossref]  [PubMed]  [PMC] 
  32. Sknepnek A, Pantić M, Matija?ević D, Miletić D, Lević S, Nedović V, et al. Novel kombucha beverage from lingzhi or reishi medicinal mushroom, ganoderma lucidum, with antibacterial and antioxidant effects. Int J Med Mushrooms. 2018;20(3):243-8. [Crossref]  [PubMed] 
  33. Saltarelli R, Ceccaroli P, Buffalini M, Vallorani L, Casadei L, Zambonelli A, et al. Biochemical characterization and antioxidant and antiproliferative activities of different Ganoderma collections. J Mol Microbiol Biotechnol. 2015;25(1):16-25. PMID: [Crossref]  [PubMed] 
  34. Ćilardžić J, Vukojević J, Stajić M, Stanojković T, Glamočlija J. Biological activity of Ganoderma lucidum basidiocarps cultivated on alternative and commercial substrate. J Ethnopharmacol. 2014;155(1):312-9. [Crossref]  [PubMed] 
  35. Veljović S, Veljović M, Nikićević N, Despotović S, Radulović S, Nik?ić M, et al. Chemical composition, antiproliferative and antioxidant activity of differently processed Ganoderma lucidum ethanol extracts. J Food Sci Technol. 2017;54(5):1312-20. [Crossref]  [PubMed]  [PMC] 
  36. Zhu XL, Chen AF, Lin ZB. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol. 2007;111(2):219-26. [Crossref]  [PubMed] 
  37. Soares AA, de Sá-Nakanishi AB, Bracht A, da Costa SM, Koehnlein EA, de Souza CG, et al. Hepatoprotective effects of mushrooms. Molecules. 2013;18(7):7609-30. [Crossref]  [PubMed]  [PMC] 
  38. Yahaya NFM, Rahman MA, Abdullah N. Therapeutic potential of mushrooms in preventing and ameliorating hypertension. Trends in Food Science & Technology. 2014;39:104-15. [Crossref] 
  39. Ma HT, Hsiesh JF, Chen ST. Anti-diabetic effects of Ganoderma lucidum. Phytochemistry. 2015;114:109-13. [Crossref]  [PubMed] 
  40. Gokce EC, Kahveci R, Atanur OM, Gürer B, Aksoy N, Gokce A, et al. Neuroprotective effects of Ganoderma lucidum polysaccharides against traumatic spinal cord injury in rats. Injury. 2015;46(11):2146-55. [Crossref]  [PubMed] 
  41. Zhang J, Gao X, Panc Y, Xua N, Jia L. Toxicology and immunology of Ganoderma lucidum polysaccharides in Kunming mice and Wistar rats. Int J Biol Macromol. 2016;85:302-10. [Crossref]  [PubMed] 
  42. Gill BS, Sharma P, Kumar R, Kumar S. Misconstrued versatility of Ganoderma lucidum: a key player in multi-targeted cellular signaling. Tumour Biol. 2016;37(3):2789-804. [Crossref]  [PubMed] 
  43. Rathore H, Prasad S, Sharma S. Mushroom nutraceuticals for improved nutrition and better human health: a review. PharmaNutrition. 2017;5(2):35-46. [Crossref] 
  44. Chang CJ, Lin CS, Lu CC, Marte J, Ko YF, Ojcius DM, et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. 2015;6:7489. [Crossref]  [PubMed]  [PMC] 
  45. Wasser SP, Weis LA. Medical properties of substances occurring in higher basidiomycetes mushrooms: current perspectives. International Journal of Medical Mushrooms. 1999;1(1):31-62. [Crossref] 
  46. Zhang H, Gong F, Feng Y, Zhang C. Flammulin purified from the fruit bodies of Flammulina velutipes (Curt .:Fr.) P. Karst. International Journal of Medical Mushrooms. 1999;1(1):89-92. [Crossref] 
  47. Martínez-Montemayor MM, Acevedo RR, Otero-Franqui E, Cubano LA, Dharmawardhane SF. Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer. Nutr Cancer. 2011;63(7):1085-94. [Crossref]  [PubMed]  [PMC] 
  48. Guggenheim AG, Wright KM, Zwickey HL. Immune modulation from five major mushrooms: application to integrative oncology. Integr Med (Encinitas). 2014;13(1):32-44.
  49. Barbieri A, Quagliariello V, Del Vecchio V, Falco M, Luciano A, Amruthraj NJ, et al. Anticancer and anti-inflammatory properties of Ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment. Nutrients. 2017;9(3):pii E210. [Crossref]  [PubMed]  [PMC] 
  50. Yuen JW, Gohel MD. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer. 2005;53(1):11-7. [Crossref]  [PubMed] 
  51. Pillai TG, Nair CK, Janardhanan KK. Polysaccharides isolated from Ganoderma lucidum occurring in Southern parts of India, protects radiation induced damages both in vitro and in vivo. Environ Toxicol Pharmacol. 2008;26(1):80-5. [Crossref]  [PubMed] 
  52. Li N, Hu YL, He CX, Hu CJ, Zhou J, Tang GP, et al. Preparation, characterisation and anti-tumour activity of Ganoderma lucidum polysaccharide nanoparticles. J Pharm Pharmacol. 2010;62(1):139-44. [Crossref]  [PubMed] 
  53. Smina TP, Nitha B, Devasagayam TPA, Janardhanan KK. Ganoderma lucidum total triterpenes induce apoptosis in MCF-7 cells and attenuate DMBA induced mammary and skin carcinomas in experimental animals. Mutat Res Genet Toxicol Environ Mutagen. 2017;813:45-51. [Crossref]  [PubMed] 
  54. Nonaka Y, Ishibashi H, Nakai M, Shibata H, Kiso Y, Abe S. Effects of the antlered form of Ganoderma lucidum on tumor growth and metastasis in cyclophosphamide-treated mice. Biosci Biotechnol Biochem. 2008;72(6):1399-408. [Crossref]  [PubMed] 
  55. Weng CJ, Yen GC. The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clin Exp Metastasis. 2010;27(5):361-9. [Crossref]  [PubMed] 
  56. Zhong JJ, Zhong J. Antimetastatic effect of ganoderic acid T in vitro through inhibition of cancer cell invasion. Process Biochemistry. 2010;45(8):1261-7. [Crossref] 
  57. Ruan W, Wei Y, Popovich DG. Distinct responses of cytotoxic Ganoderma lucidum triterpenoids in human carcinoma cells. Phytother Res. 2015;29(11):1744-52. [Crossref]  [PubMed] 
  58. Loganathan J, Jiang J, Smith A, Jedinak A, Thyagarajan-Sahu A, Sandusky GE, et al. The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes. Int J Oncol. 2014;44(6):2009-15. [Crossref]  [PubMed]  [PMC] 
  59. Hasnat MA, Pervin M, Cha KM, Kim SK, Lim BO. Anti-inflammatory activity on mice of extract of Ganoderma lucidum grown on rice via modulation of MAPK and NF-κB pathways. Phytochemistry. 2015;114:125-36. [Crossref]  [PubMed] 
  60. Lakshmi B, Ajith TA, Sheena N, Gunapalan N, Janardhanan KK. Antiperoxidative, anti-inflammatory, and antimutagenic activities of ethanol extract of the mycelium of Ganoderma lucidum occurring in South India. Teratog Carcinog Mutagen. 2003;Suppl 1:85-97. [Crossref]  [PubMed] 
  61. Dudhgaonkar S, Thyagarajan A, Sliva D. Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol. 2009;9(11):1272-80. [Crossref]  [PubMed] 
  62. Wang WJ, Wu YS, Chen S, Liu CF, Chen SN. Mushroom β-glucan may immunomodulate the tumor-associated macrophages in the lewis lung carsinoma. Biomed Res Int. 2015;2015:604385. [Crossref]  [PubMed]  [PMC] 
  63. Yao X, Li G, Xu H, Lü C. Inhibition of the JAK-STAT3 signaling pathway by ganoderic acid A enhances chemosensitivity of HepG2 cells to cisplatin. Planta Med. 2012;78(16):1740-8. [Crossref]  [PubMed] 
  64. Suprasert P, Apichartpiyakul C, Sakonwasun C, Nitisuwanraksa P, Phuackchantuck R. Clinical characteristics of gynecologic cancer patients who respond to salvage treatment with Lingzhi. Asian Pac J Cancer Prev. 2014;15(10):4193-6. [Crossref]  [PubMed] 
  65. Sun LX, Li WD, Lin ZB, Duan XS, Li XF, Yang N, et al. Protection against lung cancer patient plasma-induced lymphocyte suppression by Ganoderma lucidum polysaccharides. Cell Physiol Biochem. 2014;33(2):289-99. [Crossref]  [PubMed] 
  66. Oka S, Tanaka S, Yoshida S, Hiyama T, Ueno Y, Ito M, et al. A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci. 2010;59(1):1-6.
  67. Pillai TG, Uma Devi P. Mushroom beta glucan: potential candidate for post irradiation protection. Mutat Res. 2013;751(2):109-15. [Crossref]  [PubMed] 
  68. Wang C, Shi S, Chen Q, Lin S, Wang R, Wang S, et al. Antitumor and Immunomodulatory activities of ganoderma lucidum polysaccharides in glioma-bearing rats. Integr Cancer Ther. 2018,17(3):674-83. [Crossref]  [PubMed]  [PMC] 
  69. Gill SK, Rieder MJ. Toxicity of a traditional Chinese medicine, Ganoderma lucidum, in children with cancer. Can J Clin Pharmacol. 2008;15(2):e275-85.
  70. Jin H, Jin F, Jin JX, Xu J, Tao TT, Liu J, et al. Protective effects of Ganoderma lucidum spore on cadmium hepatotoxicity in mice. Food Chem Toxicol. 2013;52:171-5. [Crossref]  [PubMed] 
  71. Wu JG, Kan YJ, Wu YB, Yi J, Chen TQ, Wu JZ. Hepatoprotective effect of ganoderma triterpenoids against oxidative damage induced by tert-butyl hydroperoxide in human hepatic HepG2 cells. Pharm Biol. 2016;54(5):919-29. [Crossref]  [PubMed] 
  72. Chung DJ, Yang MY, Li YR, Chen WJ, Hung CY, Wang CJ. Ganoderma lucidum repress injury of ethanol-induced steatohepatitis via anti-inflammation, anti-oxidation and reducing hepatic lipid in C57BL/6J mice. J Funct Foods. 2017;33:314-22. [Crossref] 
  73. Shevelev OB, Akulov AE, Dotsenko AS, Kontsevaya GV, Zolotykh MA, Gerlinskaya LA, et al. Neurometabolic effect of altaian fungus Ganoderma lucidum (Reishi Mushrom) in rats under moderate alcohol consumption. Alcohol Clin Exp Res. 2015;39(7):1128-36. [Crossref]  [PubMed] 
  74. Aydin S, Aytac E, Uzun H, Altug T, Mansur B, Saygili S, et al. Effects of Ganoderma lucidum on obstructive jaundice-induced oxidative stress. Asian J Surg. 2010;33(4):173-80. [Crossref] 
  75. Hajjaj H, Macé C, Roberts M, Niederberger P, Fay LB. Effect of 26-oxygenosterols from Ganoderma lucidum and their activity as cholesterol synthesis inhibitors. Appl Environm Microbiol. 2005;71(7):3653-8. [Crossref]  [PubMed]  [PMC] 
  76. Sabaratnam V, Kah-Hui W, Naidu M, Rosie David P. Neuronal health-can culinary and medicinal mushrooms help? J Tradit Complement Med. 2013;3(1):62-8. [Crossref]  [PubMed]  [PMC] 
  77. Ding H, Zhou M, Zhang RP, Xu SL. [Ganoderma lucidum extract protects dopaminergic neurons through inhibiting the production of inflammatory mediators by activated microglia]. Sheng Li Xue Bao. 2010;25(62)(6):547-54.
  78. Zhang W, Zeng YS, Wang Y, Liu W, Cheng JJ, Chen SJ. [Primary study on proteomics about Ganoderma lucidium spores promoting survival and axon regeneration of injured spinal motor neurons in rats]. Zhong Xi Yi Jie He Xue Bao. 2006;4(3):298-302. [Crossref]  [PubMed] 
  79. Matsuzaki H, Shimizu Y, Iwata N, Kamiuchi S, Suzuki F, Iizuka H, et al. Antidepressant-like effects of a water-soluble extract from the culture medium of Ganoderma lucidum mycelia in rats. BMC Complement Altern Med. 2013;13:370. [Crossref]  [PubMed]  [PMC] 
  80. Huang S, Mao J, Ding K, Zhou Y, Zeng X, Yang W, et al. Polysaccharides from ganoderma lucidum promote cognitive function and neural progenitor proliferation in mouse model of Alzheimer's disease. Stem Cell Reports. 2017;8(1):84-94. [Crossref]  [PubMed]  [PMC] 
  81. Xuan M, Okazaki M, Iwata N, Asano S, Kamiuchi S, Matsuzaki H, et al. Chronic treatment with a water-soluble extract from the culture medium of ganoderma lucidum mycelia prevents apoptosis and necroptosis in hypoxia/ischemia-induced injury of type 2 diabetic mouse brain. Evid Based Complement Alternat Med. 2015;2015:865986. [Crossref]  [PubMed]  [PMC] 
  82. YouGuo C, ZongJi S, XiaoPing C. Modulatory effect of Ganoderma lucidum polysaccharides on serum antioxidant enzymes activities in ovarian cancer rats. Carbohydrate Polymers. 2009;78(2):258-62. [Crossref] 
  83. Lui T, Ma Q, Zhao L, Jia R, Zhang J, Ji C, et al. Protective effects of sporoderm-broken spores of ganderma lucidum on growth performance, antioxidant capacity and immune function of broiler chickens exposed to low level of Aflatoxin B1. Toxins (Basel). 2016;8(10):278. [Crossref]  [PubMed]  [PMC] 
  84. Chiu HF, Fu HY, Lu YY, Han YC, Shen YC, Venkatakrishnan K, et al. Triterpenoids and polysaccharide peptides-enriched Ganoderma lucidum: a randomized, double-blind placebo-controlled crossover study of its antioxidation and hepatoprotective efficacy in healthy volunteers. Pharm Biol. 2017;55(1):1041-6. [Crossref]  [PubMed]  [PMC] 
  85. Wu T, Xu B. Antidiabetic and antioxidant activities of eight medicinal mushroom species from China. Int J Med Mushrooms. 2015;17(2):129-40. [Crossref]  [PubMed] 
  86. Wang F, Zhou Z, Ren X, Wang Y, Yang R, Luo J, et al. Effect of Ganoderma lucidum spores intervention on glucose and lipid metabolism gene expression profiles in type 2 diabetic rats. Lipids Health Dis. 2015;14:49. [Crossref]  [PubMed]  [PMC] 
  87. Ni T, Hu Y, Sun L, Chen X, Zhong J, Ma H, et al. Oral route of mini-proinsulin-expressing Ganoderma lucidum decreases blood glucose level in streptozocin-induced diabetic rats. Int J Mol Med. 2007;20(1):45-51. [Crossref]  [PubMed] 
  88. Fatmawati S, Shimizu K, Kondo R. Ganoderol B: a potent α-glucosidase inhibitor isolated from the fruiting body of Ganoderma lucidum. Phytomedicine. 2011;18(12):1053-5. [Crossref]  [PubMed] 
  89. Bhardwaj N, Katyal P, Sharma AK. Suppression of inflammatory and allergic responses by pharmacologically potent fungus Ganoderma lucidum. Recent Pat Inflamm Allergy Drug Discov. 2014;8(2):104-17. [Crossref]  [PubMed] 
  90. Liu C, Yang N, Song Y, Wang L, Zib J, Zhang S, et al. Ganoderic acid C1 isolated from the Anti-asthma Formula, ASHMITM suppresses TNF-α production by mouse macrophages and peripheral blood mononuclear cells from asthma patients. Int Immunopharmacol. 2015;27(2):224-31. [Crossref]  [PubMed]  [PMC] 
  91. Li K, Zhuoa C, Teng C, Yu S, Wang X, Hu Y, et al. Effects of Ganoderma lucidum polysaccharides on chronic pancreatitis and intestinal microbiota in mice. Int J Biol Macromol. 2016;93(Pt A):904-12. [Crossref]  [PubMed] 
  92. Thyagarajan-Sahu A, Lane B, Sliva D. Reishi Max, mushroom based dietary supplement, inhibits adipocyte differentiation, stimulates glucose uptake and activates AMPK. BMC Complement Altern Med. 2011;11:74. [Crossref]  [PubMed]  [PMC] 
  93. Kim JH, Lee DH, Lee SH, Choi SY, Lee JS. Effect of Ganoderma lucidum on the quality and functionality of Korean traditional rice wine, yakju. J Biosci Bioengin. 2004;97(1):24-8. [Crossref] 
  94. Tran HB, Yamamoto A, Matsumoto S, Ito H, Igami K, Miyazaki T, et al. Hypotensive effects and angiotensin-converting enzyme inhibitory peptides of reishi (Ganoderma lingzhi) auto-digested extract. Molecules. 2014;19(9):13473-85. [Crossref]  [PubMed]  [PMC] 
  95. Abdullah N, Ismail SM, Aminudin N, Shuib AS, Lau BF. Evaluation of selected culinary-medicinal mushrooms for antioxidant and ACE inhibitory activities. Evid Based Complement Alternat Med. 2012;2012:464238. [Crossref]  [PubMed]  [PMC] 
  96. Mohamad Ansor N, Abdullah N, Aminudin N. Anti-angiotensin converting enzyme (ACE) proteins from mycelia of Ganoderma lucidum (Curtis) P. Karst. BMC Complement Altern Med. 2013;13:256. [Crossref]  [PubMed]  [PMC] 
  97. Shi Y, Cai D, Wang X, Liu X. Immunomodulatory effect of ganoderma lucidum polysaccharides (GLP) on long-term heavy-load exercising mice. Int J Vitam Nutr Res. 2012;82(6):383-90. [Crossref]  [PubMed] 
  98. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13):1546-58. [Crossref]  [PubMed] 
  99. Jayachandran M, Xiao J, Xu B. A critical review on health promoting benefits of edible mushrooms through gut microbiota. Int J Mol Sci. 2017;18(9). [Crossref]  [PubMed]  [PMC] 
  100. Jin M, Zhu Y, Shao D, Zhao K, Xu C, Li Q, et al. Effects of polysaccharide from mycelia of Ganoderma lucidum on intestinal barrier functions of rats. Int J Biol Macromol. 2017;94(Pt A):1-9. [Crossref]  [PubMed] 
  101. Guo WL, Pan YY, Li L, Li TT, Liu B, Lv XC. Ethanol extract of Ganoderma lucidum ameliorates lipid metabolic disorders and modulates the gut microbiota composition in high-fat diet fed rats. Food Funct. 2018;9(6):3419-31. [Crossref]  [PubMed] 
  102. Delzenne NM, Bindels LB. Gut microbiota: Ganoderma lucidum, a new prebiotic agent to treat obesity? Nat Rev Gastroenterol Hepatol. 2015;12(10):553-4. [Crossref]  [PubMed] 
  103. Chiu SW, Wang ZM, Leung TM, Moore D. Nutritional value of ganoderma extract and assessment of its genotoxicity and antigenotoxicity using comet assays of mouse lymphocytes. Food Chem Toxicol. 2000;38(2-3):173-8. [Crossref] 
  104. European Food Safety Authority. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (ID: 4112/4407). EFSA 2011 Journal 9;2228:56.

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com